Compare ENOV & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENOV | IMTX |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2008 | N/A |
| Metric | ENOV | IMTX |
|---|---|---|
| Price | $21.23 | $9.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $48.13 | $19.25 |
| AVG Volume (30 Days) | ★ 1.0M | 367.1K |
| Earning Date | 02-26-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,233,266,000.00 | $99,445,031.00 |
| Revenue This Year | $9.22 | N/A |
| Revenue Next Year | $4.60 | $19.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.57 | N/A |
| 52 Week Low | $21.90 | $3.30 |
| 52 Week High | $49.38 | $12.41 |
| Indicator | ENOV | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.64 | 49.15 |
| Support Level | $22.50 | $9.37 |
| Resistance Level | $24.46 | $10.36 |
| Average True Range (ATR) | 1.28 | 0.47 |
| MACD | -0.37 | 0.03 |
| Stochastic Oscillator | 0.46 | 64.48 |
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.